PHR Pharmena S.A.
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was incorporated in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.…
Industry Peers
BiotechnologyKey Statistics
About Pharmena (WSE: PHR)
›
Pharmena (WSE: PHR) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 2.710 PLN on 19 November 2026, down 21.4% over 52 weeks. Its 52-week range is 2.500 PLN to 4.320 PLN: the price is 37.3% below the high and 8.4% above the low.
Its market capitalisation is 30.18M PLN.
Pharmena reports return on equity of -28.7%, an operating margin of -228.6% and revenue down 37.3% year over year.
It holds more cash than debt, a net cash position of 107.00K PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.